Xintela AB
1XT
Company Profile
Business description
Xintela AB is a biomedical company that develops stem cell-based treatments with a focus on osteoarthritis and hard-to-heal leg wounds as well as, through the wholly-owned subsidiary Targinta, targeted antibody-based treatments for aggressive cancers such as triple-negative breast cancer and the brain tumor glioblastoma.
Contact
Medicon Village
Lund22381
SWET: +46 462756500
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
13
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,180.20 | 43.00 | -0.47% |
| CAC 40 | 8,274.57 | 53.29 | -0.64% |
| DAX 40 | 24,066.70 | 22.48 | 0.09% |
| Dow JONES (US) | 48,463.72 | 72.27 | -0.15% |
| FTSE 100 | 10,559.58 | 49.48 | -0.47% |
| HKSE | 26,255.15 | 307.83 | 1.19% |
| NASDAQ | 24,016.02 | 376.94 | 1.59% |
| Nikkei 225 | 59,549.59 | 1,415.35 | 2.43% |
| NZX 50 Index | 13,095.24 | 18.66 | 0.14% |
| S&P 500 | 7,022.95 | 55.57 | 0.80% |
| S&P/ASX 200 | 8,963.70 | 53.50 | -0.59% |
| SSE Composite Index | 4,048.63 | 21.43 | 0.53% |